{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T01:01:20Z","timestamp":1781053280283,"version":"3.54.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.leukres.2026.108235","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T08:50:14Z","timestamp":1776243014000},"page":"108235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Clinical use and adverse effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia: The role of comorbidities"],"prefix":"10.1016","volume":"166","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7792-0882","authenticated-orcid":false,"given":"Selin","family":"K\u0131r","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7647-1197","authenticated-orcid":false,"given":"Nigar","family":"Abdullayeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Y\u0131lmazer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8646-1673","authenticated-orcid":false,"given":"G\u00fcray","family":"Saydam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mine","family":"Hekimgil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z\u00fchal","family":"Demirci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7722-506X","authenticated-orcid":false,"given":"Nur","family":"Soyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2026.108235_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100825","article-title":"Chronic myeloid leukemia: modern therapies, current challenges and future directions","volume":"49","author":"Osman","year":"2021","journal-title":"Blood Rev."},{"key":"10.1016\/j.leukres.2026.108235_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00603","article-title":"Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety","volume":"9","author":"Garc\u00eda-Guti\u00e9rrez","year":"2019","journal-title":"Front Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2026.108235_bib3","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol."},{"issue":"10","key":"10.1016\/j.leukres.2026.108235_bib4","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2026.108235_bib5","first-page":"1","article-title":"Management of myeloproliferative neoplasms in the molecular era: from research to practice","volume":"42","author":"Pettit","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"10","key":"10.1016\/j.leukres.2026.108235_bib6","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.clml.2017.06.011","article-title":"Elevated cardiovascular disease risk in patients with chronic myelogenous leukemia seen in community-based oncology practices in the United States","volume":"17","author":"Coutinho","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"9","key":"10.1016\/j.leukres.2026.108235_bib7","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1007\/s00277-024-05828-3","article-title":"CML in the very elderly: the impact of comorbidities and TKI selection in a real-life multicenter study","volume":"103","author":"Rozental","year":"2024","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2026.108235_bib8","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","article-title":"Schweizerische Arbeitsgemeinschaft f\u00fcr Klinische Krebsforschung and the German CML Study Group Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV","volume":"126","author":"Saussele","year":"2015","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.leukres.2026.108235_bib9","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.leukres.2026.108235_bib10","unstructured":"T\u00fcrkiye Endokrinoloji ve Metabolizma Derne\u011fi Hipertansiyon Tan\u0131 ve Tedavi K\u0131lavuzu 2022, B\u00f6l\u00fcm 1, sayfa 7."},{"key":"10.1016\/j.leukres.2026.108235_bib11","unstructured":"IDF Diabetes Atlas 2021, 10th edition \u3008https:\/\/diabetesatlas.org\/atlas\/tenth-edition\/\u3009 (Accessed on January 17, 2022)."},{"key":"10.1016\/j.leukres.2026.108235_bib12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","author":"Ong","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2026.108235_bib13","unstructured":"Centers for Disease Control and Prevention: National Diabetes Statistics Report, \u3008https:\/\/www.cdc.gov\/diabetes\/php\/data-research\/index.html\u3009 (Accessed on October 23, 2024)."},{"key":"10.1016\/j.leukres.2026.108235_bib14","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.2337\/dc22-0242","article-title":"Undiagnosed diabetes in U.S. adults: prevalence and trends","volume":"45","author":"Fang","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.leukres.2026.108235_bib15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10654-013-9771-5","article-title":"Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults","volume":"28","author":"Satman","year":"2013","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.leukres.2026.108235_bib16","unstructured":"Onat A. TEKHARF \u00e7al\u0131\u015fmas\u0131 2009. Available at: \u3008http:\/\/tekharf.org\/\u3009 Accessed May 20, 2011."},{"key":"10.1016\/j.leukres.2026.108235_bib17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2265.1995.tb01894.x","article-title":"The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey","volume":"43","author":"Vanderpump","year":"1995","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.leukres.2026.108235_bib18","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1089\/thy.2006.0235","article-title":"Serum TSH and total T4 in the United States population and their association with participant characteristics: National Health and Nutrition Examination Survey (NHANES 1999-2002)","volume":"17","author":"Aoki","year":"2007","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.leukres.2026.108235_bib19","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/ndt\/gfq656","article-title":"A population-based survey of chronic renal disease In Turkey-the CREDIT study","volume":"26","author":"S\u00fcleymanlar","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.leukres.2026.108235_bib20","first-page":"5","article-title":"Trabzon\u2019da 30 yas ve \u00fczeri n\u00fcfusta KOAH prevalans\u0131. Toraks Dergisi 7 Y\u0131ll\u0131k Kongresi Bildiri \u00d6zetleri Antalya","author":"\u00d6zl\u00fc","year":"2004","journal-title":"Nisan"},{"issue":"7","key":"10.1016\/j.leukres.2026.108235_bib21","first-page":"556","article-title":"Data on prevalence of dyslipidemia and lipid values in turkey: systematic review and meta-analysis of epidemiological studies on cardiovascular risk factors","volume":"46","author":"Kay\u0131k\u00e7\u0131o\u011flu","year":"2018","journal-title":"Turk. Kardiyol. Dern. Ars"},{"key":"10.1016\/j.leukres.2026.108235_bib22","first-page":"164","article-title":"EUROASPIRE III: a comparison between Turkey and Europe","volume":"38","author":"Tokg\u00f6zo\u011flu","year":"2010","journal-title":"Turk. Kardiyol. Dern. Ars"},{"issue":"8","key":"10.1016\/j.leukres.2026.108235_bib23","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1111\/j.1476-5381.2011.01732.x","article-title":"Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates","volume":"165","author":"Filppula","year":"2012","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.leukres.2026.108235_bib24","unstructured":"Tasigna (nilotinib) dosing, indications, interactions, adverse effects, and more\". Medscape Reference. WebMD. Archived from the original on July 17, 2021. Retrieved January 25, 2014."},{"issue":"6","key":"10.1016\/j.leukres.2026.108235_bib25","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s00280-007-0562-0","article-title":"Dermatitis after suspected imatinib levothyroxine interaction in a patient with gastrointestinal stromal tumor","volume":"61","author":"Cholongitas","year":"2008","journal-title":"Cancer Chemother. Pharm."},{"issue":"4","key":"10.1016\/j.leukres.2026.108235_bib26","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.clpt.2005.06.010","article-title":"Imatinib induces hypothyroidism in patients receiving levothyroxine","volume":"78","author":"de Groot","year":"2005","journal-title":"Clin. Pharm. Ther."},{"issue":"10","key":"10.1016\/j.leukres.2026.108235_bib27","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/sj.bjc.6604355","article-title":"Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability","volume":"98","author":"Widmer","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.leukres.2026.108235_bib28","unstructured":"Wrz B., Valles B., Parkinson A., Madan A., Probst A., Zimmerlin A., Gut J. CYP3A4 and CYP2A6 are involved in the biotransformation of letrozole. ISSX Proc. 1996;10:359. Abstract."},{"key":"10.1016\/j.leukres.2026.108235_bib29","unstructured":"Product information. Novartis Pharmaceutical Canada Inc. Prescribing information femara1 (letrozole) \u3008http:\/\/www.pharma.ca.novartis.com\/downloads\/e\/femara_scrip_e.pdf\u3009 (online 23 April 2007)."},{"issue":"10","key":"10.1016\/j.leukres.2026.108235_bib30","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1093\/annonc\/mdq061","article-title":"Clinical features of interstitial lung disease induced by standard chemotherapy (FOLFOX or FOLFIRI) for colorectal cancer","volume":"21","author":"Shimura","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.leukres.2026.108235_bib31","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3393\/jksc.2011.27.5.266","article-title":"Oxaliplatin-induced pulmonary fibrosis: two case reports","volume":"27","author":"Ryu","year":"2011","journal-title":"J. Korean Soc. Coloproctol."},{"key":"10.1016\/j.leukres.2026.108235_bib32","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2174\/157488612802715672","article-title":"Oxaliplatin-induced lung toxicity","volume":"7","author":"Prochilo","year":"2012","journal-title":"Case Rep. Rev. Lit. Curr. Drug Saf."},{"issue":"3","key":"10.1016\/j.leukres.2026.108235_bib33","first-page":"151","article-title":"Evaluation of oxaliplatin-induced pulmonary toxicity in rats","volume":"23","author":"Kalemci","year":"2019","journal-title":"Conte Oncol. (Pozn. )"},{"issue":"5","key":"10.1016\/j.leukres.2026.108235_bib34","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s00280-009-0935-7","article-title":"Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4\u2032-methanol-bisbenzonitrile in vitro","volume":"64","author":"Jeong","year":"2009","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.leukres.2026.108235_bib35","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/35077225","article-title":"Oncogenic kinase signaling","volume":"411","author":"Blume-Jensen","year":"2001","journal-title":"Nature"},{"issue":"11-12","key":"10.1016\/j.leukres.2026.108235_bib36","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/j.1552-4604.1984.tb02758.x","article-title":"Do beta blockers differ in their effects on hepatic microsomal enzymes and liver blood flow?","volume":"24","author":"Parker","year":"1984","journal-title":"J. Clin. Pharm."},{"issue":"5","key":"10.1016\/j.leukres.2026.108235_bib37","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/00912700022009152","article-title":"Effect of metoprolol and verapamil administered separately and concurrently after single doses on liver blood flow and drug disposition","volume":"40","author":"Bauer","year":"2000","journal-title":"J. Clin. Pharm."},{"issue":"8","key":"10.1016\/j.leukres.2026.108235_bib38","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","article-title":"Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib","volume":"117","author":"Haouala","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108235_bib39","first-page":"053","article-title":"Tirozin Kinaz \u0130nhibit\u00f6rleri ile Tedavi Edilen Onkoloji Hastalar\u0131nda Klinik Eczac\u0131l\u0131k Uygulamalar\u0131","volume":"28","author":"Kamer","year":"2018","journal-title":"Int. J. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2026.108235_bib40","doi-asserted-by":"crossref","first-page":"6538","DOI":"10.3390\/ijms22126538","article-title":"Nanotechnology of tyrosine kinase inhibitors in cancer therapy: a perspective","volume":"22","author":"Russo","year":"2021","journal-title":"Int J. Mol. Sci."}],"updated-by":[{"DOI":"10.1016\/j.leukres.2026.108251","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000}},{"DOI":"10.1016\/j.leukres.2026.108251","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000}}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:38:21Z","timestamp":1781051901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626000792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":40,"alternative-id":["S0145212626000792"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108235","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical use and adverse effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia: The role of comorbidities","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108235","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108235"}}